MethylGene Inc. (TSX: MYG) has appointed Dr. Henry J. Fuchs, MD, to its board of directors.
Dr. Fuchs is currently EVP & CMO of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Prior to joining BioMarin, Dr. Fuchs has held positions of EVP & CMO with Onyx Pharmaceuticals (NASDAQ: ONXX), VP of Clinical Affairs, then President & CEO and finally CEO with Ardea Biosciences (NASDAQ :RDEA). Dr. Fuchs has also held various positions at Genentech.
Dr. Fuchs holds an M.D. from George Washington University and a B.A. in Biochemical Sciences from Harvard University.
